Joel S. Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities, Inc., Honored with the Prestigious Richard J. Bolte Sr. Award from the Science History Institute Museum & Library in Recognition of His Consequential Long-Term Impact on the Life Science Industry

Rhea-AI Summary

Alexandria Real Estate Equities (NYSE: ARE) announced that founder and executive chairman Joel S. Marcus will receive the Richard J. Bolte Sr. Award on May 6, 2026.

Highlights: founded 1994 with $19M Series A; $20.44B market cap; 35.8 million RSF operating asset base as of March 31, 2026; partnership launching the MAP-D precision medicine depression study.

Positive

• $20.44B total market capitalization as of March 31, 2026
• 35.8 million RSF operating asset base in North America
• Founded in 1994 with $19M Series A capital
• Nearly half of FDA novel therapies since 2013 marketed by Alexandria tenants
• Leading partnership for MAP-D to build a large depression biomarker dataset

Negative

• None.

News Market Reaction – ARE

+4.63%

9 alerts

+4.63% Session close to close

$8.10B Market Cap

0.1x Rel. Volume

In the May 6 session, ARE gained 4.63%, reflecting a moderate positive market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights recognition of Alexandria’s executive chairman for long-term contributi...

Analysis

This announcement highlights recognition of Alexandria’s executive chairman for long-term contributions to the life science ecosystem and underscores the company’s growth to a $20.44 billion market cap and 35.8 million RSF operating base. It also emphasizes a partnership to advance precision medicine approaches in depression, addressing an economic burden of $380 billion annually. In context of recent mixed fundamental trends and consistent reputational awards, investors may watch how mission-driven initiatives relate to future operating performance.

Key Figures

Series A capital: $19 million Market capitalization: $20.44 billion Operating asset base: 35.8 million RSF +3 more

6 metrics

Series A capital $19 million Initial funding at company founding in 1994

Market capitalization $20.44 billion Total market cap as of March 31, 2026 from article

Operating asset base 35.8 million RSF Operating asset base in North America as of March 31, 2026

Adults with major depressive disorder more than 21 million Adults affected annually in the U.S. cited in article

Treatment-resistant proportion nearly one-third Share of adults with treatment-resistant depression

Economic burden of depression $380 billion Annual economic burden of major depressive disorder

Historical Context

5 past events · Latest: Apr 27 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Quarterly earnings	Negative	-11.3%	1Q26 showed strong GAAP profit from a debt gain but weaker core metrics.
Apr 21	Peer governance critique	Negative	-2.4%	Land & Buildings criticized WELL’s compensation plan; broader REIT governance concerns.
Apr 02	Reputation award	Positive	-0.4%	Named one of the Most Trustworthy Companies in America by Newsweek.
Mar 11	CSR recognition	Positive	+0.2%	Recognized as one of the Most Charitable Companies in America by Newsweek.
Mar 02	Dividend declaration	Positive	-2.6%	Declared $0.72 1Q26 dividend with a stated 5.2% yield and 33% payout ratio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ARE-specific positive reputational and dividend news often saw flat-to-negative reactions, while mixed fundamentals in 1Q26 earnings aligned with a sharp selloff.

Recent Company History

Over the last few months, Alexandria reported 1Q26 results on Apr 27 with GAAP net income per share of $2.10 but weaker FFO and operating metrics, and the stock fell 11.3%. Earlier, the company received trustworthiness and charitable recognitions in March–April with minimal price impact. A 1Q26 dividend of $0.72 per share on Mar 02 coincided with a modest decline. Against that backdrop, today’s leadership award and impact-focused narrative extend the theme of reputation and mission-driven positioning rather than fundamentals.

Key Terms

series a capital, rsf, immunotherapy, major depressive disorder, +3 more

7 terms

series a capital financial

"Since the company's founding in 1994 as a garage startup with $19 million in Series A capital"

Series A capital is the money a startup raises in its first major round of outside investment, typically in exchange for shares that give those investors extra protections and some say in how the company is run. Think of it like a small business taking on a growth partner to expand: it signals the company has moved beyond the idea stage, sets an early valuation, and affects ownership, future fundraising prospects, and the potential upside or risk for investors.

rsf technical

"a 35.8 million RSF operating asset base in North America as of March 31, 2026"

RSF stands for rentable square feet, the amount of space a landlord charges rent for in a commercial property, typically including a tenant’s usable area plus a share of common spaces like lobbies and hallways. Investors use RSF the way a restaurant owner counts seats—it's the unit that determines potential rental income, occupancy metrics and how properties are compared or valued, so changes in RSF affect revenue and real estate valuation.

immunotherapy medical

"Keytruda®, a transformative globally best-selling immunotherapy that redefined cancer treatment"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

major depressive disorder medical

"advance the development of new treatments for major depressive disorder at the individual patient level"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

precision medicine medical

"by advancing a precision medicine framework for depression"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

biomarkers medical

"to identify subgroups and validate biomarkers for depression"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

fda regulatory

"with nearly half of the novel therapies approved by the FDA since 2013"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif., May 6, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, today announced that Joel S. Marcus, executive chairman and founder, will receive the Richard J. Bolte Sr. Award during a gala and ceremony hosted this evening by the Science History Institute Museum & Library in Old City, Philadelphia. The Richard J. Bolte Sr. Award honors exemplary leaders who provide unique and consequential products or services vital to the continuing growth and development of the chemical and molecular life science communities.

"Joel understands that building a thriving life science ecosystem is about far more than real estate – it's about people. His work reflects a unique mission-driven approach, complemented by heartfelt philanthropy and a deep investment in the success of others," said David Cole, president and chief executive officer of the Science History Institute. Mr. Marcus joins an esteemed cohort of past awardees, including Lita Nelsen (2025), a global authority on university technology transfer and commercialization; Dr. Eugene Garfield (2007), whose work fundamentally shaped how scientific research is measured and evaluated worldwide; Dr. Alan Walton (2013), who was instrumental in the development and funding of the Human Genome project and former member of Alexandria's Board of Directors; and Dr. Jerry Sudarsky (2008), Alexandria's co-founder.

Mike "Coach K" Krzyzewski, Naismith Memorial Basketball Hall of Fame coach, five-time national champion as former head coach of Duke basketball and six-time gold medalist as former head coach of the U.S. Men's National Team, reflected on Joel as a leader and their longstanding friendship, sharing, "Joel's really the ultimate team player. He's a very curious leader, which are the best leaders because they listen and they want to expand what they do. They know that in doing well, they can help others do well. He's got a beautiful heart and is completely trustworthy. And he has your back. He wants other people to have the opportunity to be successful. There's that expression – one-of-a-kind – Joel is one-of-a-kind."

Since the company's founding in 1994 as a garage startup with $19 million in Series A capital, Mr. Marcus has pioneered the life science real estate niche and led the remarkable growth of Alexandria into a one-of-a-kind NYSE-listed company with a $20.44 billion total market capitalization and a 35.8 million RSF operating asset base in North America as of March 31, 2026. Today, Alexandria provides vital support to the engine that catalyzes life-changing and life-saving innovation, with nearly half of the novel therapies approved by the FDA since 2013 marketed by Alexandria tenants.

Roger Perlmutter, chief executive officer of Eikon Therapeutics and former president of Merck Research Laboratories, where he led the development of Keytruda^®, a transformative globally best-selling immunotherapy that redefined cancer treatment, stated, "Joel really understands the importance of community from all of its different perspectives. It begins with vision, but behind that vision is a dogged attention to detail. As a visionary he saw early on, in a very purposeful way, you could create communities that would permit biomedical researchers to do more than what they imagined, and he could facilitate that. He could create spaces, attract individuals and bring their power to bear on the way in which people work together. And if he did that well, and he supported environments that enhanced communication, then that would accelerate progress. And he was absolutely right."

May is Mental Health Awareness Month, and each year, major depressive disorder affects more than 21 million adults, nearly one-third of whom suffer from treatment-resistant depression. The economic burden exceeds $380 billion annually, rivaling the nation's largest drivers of chronic disease-related health care spending. Currently, depression is treated with a one-size-fits-all approach, leaving many patients to cycle through therapies for months or years without success. Guided by his mission-driven commitment to advance human health and the company's unrivaled ability to catalyze collaboration, Mr. Marcus is leading Alexandria's partnership with the Foundation for the National Institutes of Health (FNIH) to address this severe unmet need by advancing a precision medicine framework for depression. The Multi-Level Assessment & Phenotyping in Depression (MAP-D) project will build one of the most comprehensive datasets ever assembled to identify subgroups and validate biomarkers for depression and, ultimately, advance the development of new treatments for major depressive disorder at the individual patient level.

This latest recognition from the Science History Institute reinforces the consequential impact of Mr. Marcus' egoless leadership, which has helped shape the culture of idea meritocracy and operational excellence of Alexandria's best-in-class team; fortify its unmatched ability to develop and maintain trusted relationships with top life science entities; and support the company's strategic leadership in creating long-term value for its investors.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's impact on the development of novel medicines, treatments, therapies, and cures and on human health and well-being; Alexandria's thought leadership, collaborations, investments, and progress relating to the treatment of depression; the launch, goals, and efforts of the MAP-D program; the likelihood of continued commitment and efforts by Alexandria to foster collaboration that improves human health; and Alexandria's ability to meet and anticipate industry needs and maintain strategic relationships. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Sara Cohen, Assistant Vice President – Corporate Strategy, (646) 799-2617, scohen@are.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/joel-s-marcus-executive-chairman-and-founder-of-alexandria-real-estate-equities-inc-honored-with-the-prestigious-richard-j-bolte-sr-award-from-the-science-history-institute-museum--library-in-recognition-of-his-consequenti-302762925.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What award did Joel S. Marcus of ARE receive on May 6, 2026?

He received the Richard J. Bolte Sr. Award for long-term impact on life sciences. According to the company, the award recognizes leaders providing consequential products or services to chemical and molecular life science communities.

What are Alexandria's key corporate metrics reported as of March 31, 2026 (ARE)?

Alexandria reported a $20.44 billion market capitalization and 35.8 million RSF operating assets. According to the company, those figures reflect its North American life science real estate footprint.

What is the MAP-D project announced by ARE and its purpose?

MAP-D is a precision medicine study to identify depression subgroups and validate biomarkers. According to the company, it will assemble a comprehensive dataset to support personalized treatments for major depressive disorder.

How has Joel Marcus influenced Alexandria's role in life science commercialization (ARE)?

Marcus built Alexandria into a specialized life science real estate platform supporting innovation clusters. According to the company, that approach helped tenants advance nearly half of FDA novel therapies since 2013.

When was Alexandria founded and what initial capital did it raise (ARE)?

Alexandria was founded in 1994 and raised $19 million in Series A capital. According to the company, that seed funding launched its focus on life science megacampus development.